Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Urothelial Carcinoma: early-phase trial registry
37 of 86 indexed Urothelial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #160 of 28,707 conditions by registered trial count.
86 US clinical trials · 37 currently recruiting · #160 of 28,707 conditions by registered trial count
Urothelial Carcinoma: 86 US clinical trials tracked, 37 recruiting.
Urothelial Carcinoma is the subject of 86 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 59 in Phase 1-2 (earlier-stage). The most active sponsor is Fox Chase Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition urothelial-carcinoma
OPEN 37 | RECR 43% | LATE 6 | EARLY 59 | RANK #160 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Systemic Lupus Erythematosus (43% recruiting · 100 trials)
Urothelial Carcinoma lists 37 open slots (43% of 86 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Urothelial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Urothelial Carcinoma is recruiting above its size-band peers.
37 of 86 indexed trials (43%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Urothelial Carcinoma trials is spread across many organizations.
Fox Chase Cancer Center accounts for 6 of 86 trials (7%). 63 distinct sponsors appear on at least one study for this condition label.
-
Typical Urothelial Carcinoma enrolment sits around 70 participants.
Median target enrolment is 70 among the 86 trials that report a genuine target (sentinel values excluded). 50 of those (58.1%) plan for fewer than 100 participants.
-
Urothelial Carcinoma research is mostly interventional.
75 interventional and 11 observational studies make up this index (87.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
86 total, page 2 of 2
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
NCT05923190
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT02989584
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Merck Sharp & Dohme
NCT05562830
Pembrolizumab in Muscle-invasive Bladder Cancer
Matthew Galsky
NCT05406713
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio
NCT03228667
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT03093922
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
Fox Chase Cancer Center
NCT03179943
Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
University of Oklahoma
NCT04004442
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
Brigham and Women's Hospital
NCT04018053
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02845323
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
NCT05137262
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT05335941
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
H. Lee Moffitt Cancer Center and Research Institute
NCT05768347
The Cxbladder Monitoring Study
Pacific Edge Limited
NCT02700659
STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA
Pacific Edge Limited
NCT03988309
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
Matthew Milowsky, MD
NCT02643043
Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
AstraZeneca
NCT03788746
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor
NCT03517488
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
Basilea Pharmaceutica
NCT04045613
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
NCT04200963
Cabozantinib for Advanced Urothelial Cancer
National Cancer Institute (NCI)
NCT01688999
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
NCT04666688
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America
NCT02482168
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT03829436
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
Bayer
NCT03473756
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Hoosier Cancer Research Network
NCT01524991
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
OncoNano Medicine
NCT03735680
A Study of a Personalized Neoantigen Cancer Vaccine
Gritstone bio
NCT03639714
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
University of Texas Southwestern Medical Center
NCT02986867
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03039413
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
NCT04452214
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT03758781
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
NCT04601402
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
NCT02788201
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy
Vyriad
NCT03171493
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma
NCT05136898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 22 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Urothelial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Urothelial Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Urothelial Carcinoma page
86 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Urothelial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fox Chase Cancer Center sponsors the most Urothelial Carcinoma trials on record, review their full trial history before evaluating a specific study. See Fox Chase Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urothelial Carcinoma condition card totals 86 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.